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Background: About 10-15% of adult gastrointestinal stromal tumors (GIST) and the vast majority of pediatric GIST
do not harbour KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations (J Clin Oncol 22:3813–3825,
2004; Hematol Oncol Clin North Am 23:15–34, 2009). The molecular biology of these GIST, originally defined as KIT/
PDGFRA wild-type (WT), is complex due to the existence of different subgroups with distinct molecular hallmarks,
including defects in the succinate dehydrogenase (SDH) complex and mutations of neurofibromatosis type 1 (NF1), BRAF,
or KRAS genes (RAS-pathway or RAS-P).
In this extremely heterogeneous landscape, the clinical profile and molecular abnormalities of the small subgroup
of WT GIST suitably referred to as quadruple wild-type GIST (quadrupleWT or KITWT/PDGFRAWT/SDHWT/RAS-PWT)
remains undefined. The aim of this study is to investigate the genomic profile of KITWT/PDGFRAWT/SDHWT/RAS-PWT
GIST, by using a massively parallel sequencing and microarray approach, and compare it with the genomic profile
of other GIST subtypes.
Methods: We performed a whole genome analysis using a massively parallel sequencing approach on a total of
16 GIST cases (2 KITWT/PDGFRAWT/SDHWT and SDHBIHC+/SDHAIHC+, 2 KITWT/PDGFRAWT/SDHAmut and SDHBIHC-/
SDHAIHC- and 12 cases of KITmut or PDGFRAmut GIST). To confirm and extend the results, whole-genome gene
expression analysis by microarray was performed on 9 out 16 patients analyzed by RNAseq and an additional 20
GIST patients (1 KITWT/PDGFRAWT SDHAmut GIST and 19 KITmut or PDGFRAmut GIST). The most impressive data were
validated by quantitave PCR and Western Blot analysis.
Results: We found that both cases of quadrupleWT GIST had a genomic profile profoundly different from both
either KIT/PDGFRA mutated or SDHA-mutated GIST. In particular, the quadrupleWT GIST tumors are characterized by
the overexpression of molecular markers (CALCRL and COL22A1) and of specific oncogenes including tyrosine and
cyclin- dependent kinases (NTRK2 and CDK6) and one member of the ETS-transcription factor family (ERG).
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Conclusion: We report for the first time an integrated genomic picture of KITWT/PDGFRAWT/SDHWT/RAS-PWT GIST,
using massively parallel sequencing and gene expression analyses, and found that quadrupleWT GIST have an
expression signature that is distinct from SDH-mutant GIST as well as GIST harbouring mutations in KIT or PDGFRA.
Our findings suggest that quadrupleWT GIST represent another unique group within the family of gastrointestintal
stromal tumors.
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QuadrupleWTBackground
About 10-15% of adult gastrointestinal stromal tumors (GIST)
and the vast majority of pediatric GIST do not harbour
KIT or platelet-derived growth factor receptor alpha
(PDGFRA) mutations [1,2]. These GIST were originally
defined as KIT/PDGFRA wild-type (KITWT/PDGFRAWT)
and generally are less sensitive to tyrosine-kinase inhibi-
tors [3-5]. Their molecular biology is heterogeneous as
evidence by the existence of different subgroups with
distinct molecular abnormalities (Figure 1). KITWT/
PDGFRAWT GIST can be divided into two main groups
according to the succinate dehydrogenase subunit B
(SDHB) immunohistochemical status (IHC): SDHB posi-
tive (SDHBIHC+), or type 1 GIST which, includes neuro-
fibromatosis type 1 (NF1)-mutated GIST and some
sporadic KITWT/PDGFRAWT GIST. The second group of
KITWT/PDGFRAWT, called as type 2 GIST, is character-
ized by a lack of SDHB protein expression (SDHBIHC-). In
some cases SDHBIHC- is due to germline and/or de novo
mutations of any of the four SDH subunits (SDHAmut)
[6-8]. The SDHBIHC- includes additional subgroups that
can be distinguished on the basis of the SDHA IHC status,
which strictly correlates with the presence of SDHA-
inactivating mutations (SDHAmut) [9-16]. In particular,
SDHBIHC-/SDHAIHC- GIST include a subgroup of young
adult women patients with a well defined clinical and bio-
logical profile, generally characterized by the gastric primary
tumour localization, a predominantly mixed epithelioid and
spindle cell morphology, diffuse IHC positivity for KIT and
discovered on gastrointestinal stromal tumours 1 (DOG1),
frequent lymph node metastases, and an indolent course of
disease even if metastasis is present [17]. Moreover, they
are characterized by overexpression of the insulin growth
factor 1 receptor (IGF1R) [18-21]. On the contrary,
SDHBIHC-, but SDHAIHC+ subgroup include 1) cases of syn-
dromic GIST arising from the Carney-Stratakis Syndrome
(CSS), that are characterized by SDHB, SDHC or SDHD in-
activating mutations (SDHBmut, SDHCmut, or SDHDmut);
and 2) cases of Carney Triad (CT), that lack SDHx-muta-
tions [6,22-24]. More rarely, SDHBIHC-/SDHAIHC+ sub-
group may include sporadic KITWT/PDGFRAWT GIST
characterized by SDHB, −C or D mutations (most of them
germline, and in few cases by SDHA mutations), arisingmainly from the stomach, with a lesser female prevalence,
but histologically similar to SDHAIHC- GIST [15].
The SDHBIHC+ subgroup includes cases of NF1-mu-
tated GIST, that are commonly intestinal, multifocal and
have an IGF1R negative staining, and also sporadic
KITWT/PDGFRAWT GIST, arising in the adult from any
part of gastrointestinal tract [15,21,25]. In about 15% of
cases of sporadic KITWT/PDGFRAWT GIST there may
be an activating mutation in BRAF or, more rarely, RAS
[26-28]. Taken together, cases of BRAF, RAS, or NF1
mutant GIST can be referred to as RAS-pathway (RAS-P)
mutant GIST (RAS-Pmut).
In this extremely heterogeneous landscape, the clinical
profile and molecular abnormalities of the small sub-
group of WT GIST suitably referred to as quadruple
wild-type GIST (quadrupleWT or KITWT/PDGFRAWT/
SDHWT/RAS-PWT) remains undefined [29]. The aim of
this study is to investigate the genomic profile of
KITWT/PDGFRAWT/SDHWT/RAS-PWT GIST, by using a
massively parallel sequencing and microarray approach,
and compare it with the genomic profile of other GIST
subtypes.
Results and discussion
Whole-Transcriptome Paired-End RNA Sequencing and
copy number analysis
Whole-Transcriptome Paired-End RNA Sequencing was
performed on a total of 16 GIST samples, of which 2
were KITWT/PDGFRAWT without SDH-inactivating mu-
tations and SDHBIHC+/SDHAIHC+ (GIST_133 and
GIST_127), 2 were KITWT/PDGFRAWT/SDHAmut and
SDHBIHC-/SDHAIHC- (GIST_7 and GIST_10), and 12
were KITmut or PDGFRAmut. The principal component
analysis showed that both GIST_133 and GIST_127
(KITWT/PDGFRAWT/SDHWT and SDHBIHC+/SDHAIHC+)
are characterized by a gene expression profile profoundly
different from both GIST_7 and GIST_10 (KITWT/
PDGFRAWT/SDHAmut and SDHBIHC/SDHAIHC), while
clustering in proximity of a subset of KITmut or PDGFRAmut
GIST (Figure 2A).
To investigate the presence of novel mutations or
small ins/del in the whole coding regions of KIT and
PDGFRA we analyzed whole transcriptome sequencing
Figure 1 The complexity of KITWT/PDGFRAWT GIST molecular biology. KITWT/PDGFRAWT GIST could be firstly divided two main group
according to the SDHB immunohistochemical status: SDHBIHC+ (including NF1-mutated GIST and sporadic KITWT/PDGFRAWT GIST with or without
KRAS/BRAF mutations) and SDHBIHC- or SDH-deficient GIST. The latter could be further divided according to the SDHA immunohistochemical status:
SDHBIHC-/SDHAIHC- GIST (pediatric type or young adult GIST characterized by germline or somatic inactivating SDHA mutations) and SDHBIHC/
SDHAIHC+ GIST (including Carney-Stratakis Syndrome-related GIST, characterized by germline or somatic inactivating SDHB, −C, −D mutations,
Carney Triad-related GIST that lack SDHx mutations, and sporadic KITWT/PDGFRAWT GIST, characterized by germline or somatic inactivating SDHB, −C, −D
mutations and SDHA mutations, reported in only three cases [15]. In red the subset of KITWT/PDGFRAWT GIST referred to as quadrupleWT GIST (KITWT/
PDGFRAWT/SDHWT/RAS-PWT), that represent the subject of this study.
Figure 2 Principal Component Analysis (PCA) performed on samples analyzed with RNA-seq (Figure 2A) and microarray (Figure 2B).
In both cases the patients with SDHA mutations are arranged in a strongly separated cluster (yellow points), as were the KITWT/PDGFRAWT/SDHWT/
RAS-PWT samples (red point) although closer to KIT or PDGFRA mutated (respectively blue and green point).
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private or cryptic mutations. Moreover, no NF-1, BRAF,
RAS mutations were found by whole transcriptome se-
quencing. Therefore, the GIST from these two patients
were KITWT/PDGFRAWT/SDHWT/RAS-PWT, or quadru-
pleWT GIST. Analysis of deleterious mutations from
whole transcriptome sequencing did not identify any
known oncogenic event or shared alteration in the two
patients (Additional file 1: Table S1). Copy number ana-
lysis was performed on the two KITWT/PDGFRAWT/
SDHWT/RAS-PWT GIST: GIST_133 showed no genomic
imbalances, while GIST_127 harbors several macroscopic
cytogenetic alterations, including loss of chromosome
arms 14q and 22q frequently observed in KIT/PDGFRA
mutated GIST.
Gene expression analysis
To confirm and extend the results, whole-genome gene
expression analysis by microarray was performed on 9
out 16 patients analyzed by RNAseq and an additional 20
GIST patients (1 KITWT/PDGFRAWT SDHAmut GIST and
19 KITmut or PDGFRAmut GIST). The principal compo-
nent analysis confirmed that both KITWT/PDGFRAWT/
SDHWT/RAS-PWT GIST have a genetic profile significantlyFigure 3 Representation of top-scoring genes significantly over-expre
SDHAmut, KITmut and PDGFRAmut), when each of them is compared widifferent from all three KITWT/PDGFRAWT/SDHAmut
GIST, and cluster in close proximity to some KITmut GIST
samples (Figure 2B). Supervised gene expression ana-
lysis revealed the presence of specific genetic signatures
characterizing the different molecular subgroups of
GIST (Figure 3); the SDHAmut group showed a gene sig-
nature mainly characterized by the over-expression of
IGF1R (p value 2.7X10−11) and of neural markers (LHX2,
KIRREL3) [30], whereas as expected, all PDGFRAmut GIST
were clearly separated from KITmut GIST, especially for
the expression of PDGFRA.
The quadrupleWT (KITWT/PDGFRAWT/SDHWT/RAS-PWT)
samples were characterized by a distinct gene expres-
sion profile (Figure 4), with 65 genes over-expressed or
under-expressed (p value < 0.005) compared with all
the other GIST molecular subgroups. GSEA analysis of
the transcriptional profile of quadrupleWT tumors
showed enrichment of Polycomb target genes with re-
spect to SDHAmut GIST, in particular of the classes of
PRC2 targets (p value 0.043) and H3K27-bound genes
(p value 0.021). The function of the upregulated genes
was related to cell cycle progression and MAPK signal-
ing, ad exemplified by increased expression of SKP2,
CDK6, FGF4, NTRK2). The quadrupleWT GIST tumorsssed in the four GIST classes, (KITWT/PDGFRAWT/SDHWT/RAS-PWT,
th all other cases together.
Figure 4 Unsupervised hierarchical clustering representation of differential expressed genes (P-value < 0.005) in KITWT/PDGFRAWT/
SDHWT/RAS-PWT GIST with respect to the other GIST classes (SDHxmut, KITmut and PDGFRAmut).
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markers (CALCRL and COL22A1) and of specific oncogenes
including tyrosine and cyclin- dependent kinases (NTRK2
and CDK6) and one member of the ETS-transcription
factor family (ERG). Overexpression of CALCRL, COL22A1,
NTRK2 (TrkB) and of the ETS-transcription factor ERG
was confirmed by quantitative PCR, showing that only the
KITWT/PDGFRAWT/SDHWT/RAS-PWT GIST subgroup
expressed these molecular markers and possible therapeutic
targets (Figure 5). NTRK2 protein expression level was also
evaluated by Western Blot analysis and its overexpression
in quadrupleWT GIST was confirmed (Additional file 2:
Figure S1). No mutations, gene fusions or amplifications
were identified in NTRK2 and ERG.
Discussion
The pathogenesis and underlying biology of KITWT/
PDGFRAWT with intact SDH complex (SDHxWT) andnon-mutated RAS-pathway members (RAS-PWT) suit-
ably referred to as quadrupleWT GIST remains un-
defined. In the present study, we performed a whole
genome analysis using a massively parallel sequencing
approach on a total of 16 GIST cases that included 2
KITWT/PDGFRAWT/SDHWT and SDHBIHC+/SDHAIHC+,, 2
KITWT/PDGFRAWT/SDHAmut and SDHBIHC-/SDHAIHC-
and 12 cases of KITmut or PDGFRAmut GIST. Notably, we
found that both cases of quadrupleWT GIST had a tran-
scriptome profile profoundly different from both KIT/
PDGFRA mutated and SDHA-mutated GIST, suggesting a
different molecular background underlying quadrupleWT
GIST. Since both cases of KITWT/PDGFRAWT/SDHWT
lacked mutations of BRAF, RAS family members or NF1,
the GIST of these two patients was classified KITWT/
PDGFRAWT/SDHWT/RAS-PWT or quadrupleWT GIST.
We further validated our data using genome wide gene
expression analysis, performed on 9 cases from a previous
Figure 5 Quantitative PCR estimation of ERG, NTRK2, CALCRL and COL22A1 expression in GIST. Relative expression of ERG (upper left
panel), NTRK2 (upper right panel), CALCRL (lower left panel) and COL22A1 (lower right panel) mRNA in the two KITWT/PDGFRAWT/SDHWT/RAS-PWT
GIST in respect to the others molecular subgroups (4 SDHxmut, 19 KITmut and 10 PDGFRAmut GIST). Significance was estimated by the Student T-test:
*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001.
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cases (1 KITWT/PDGFRAWT/SDHAmut GISTand 19 KITmut
or PDGFRAmut GIST). This larger analysis confirmed the
unique gene expression signature of the two quadrupleWT
GIST compared to KIT mutant, PDGFRA mutant or
SDHA-mutant GIST. Interestingly, the gene signatures of
the quadrupleWT GIST, which both arose in the small intes-
tine, clustered in close proximity to a single KITmut GIST
sample (GIST_13). This case was a small intestine GIST of
intermediate risk of relapse radically resected from a 46 year
old; it harbored an exon 11 KIT point mutation (KIT exon
11 V559D). Our current sample size does not allow us to
draw definitive conclusions, but we hypothesize that the in-
testinal origin of all three tumors may have influenced the
gene signature. However, several other cases of small intes-
tinal origin did not cluster near the cases of quadrupleWT
GIST. The influence of the tissue of origin on the gene sig-
nature is consistent with the recent data by Beadling et al.,
who described five cluster groups among 136 GIST patients
(53 KITmut, 12 PDGFRAmut, 65 adult KITWT/PDGFRAWT
and 7 pediatric KITWT/PDGFRAWT) defined by the expres-
sion patterns of 14 target genes, that were in some cases
paralleled by the location of the primary tumour [31].
Using a supervised analysis, we found four gene clus-
ter subgroups based on KIT/PDGFRA/SDH-mutational
status. Due to the rarity of RAS-P mutated GIST, we did
not have any cases suitable for these genomic studies.
Consistent with previous reports, KITWT/PDGFRAWT/SDHAmut GIST over-expressed IGF1R, further confirm-
ing the potential role of this receptor as a target or diag-
nostic marker for this specific molecular subgroup
[18-21]. Moreover, as already described, the gene signa-
ture of KITWT/PDGFRAWT/SDHAmut GIST was largely
characterized by the expression of neural-commitment
transcription markers, in support of the theory that this
subgroup may have a different cellular origin or may de-
rive from interstitial cells of Cajal (ICCs) during a differ-
ent differentiation step, such as from precursors of ICCs
[30]. Notably, both quadrupleWT GIST had a distinct
gene expression signature that was separated from the
KITWT/PDGFRAWT/SDHAmut GIST. Amongst the dif-
ferentially expressed genes, it is interesting to note the
over-expression of CALCRL, a G protein-coupled receptor
that acts as a receptor for adrenomedullin and calcitonin
gene-related peptide (CGRP), and is strongly expressed by
in several vascular tumours and types of gliomas [32-35].
Also of interest, we found over-expression of COL22A1, a
member of the collagen protein family which specifically
localizes to tissue junctions and acts as a cell adhesion lig-
and for skin epithelial cells and fibroblasts [36]. Taken to-
gether, these findings may suggest the potential role of
CALCRL and COL22A1 as diagnostic markers for the
identification of this GIST subgroup. This would need to
be validated in a larger series of GIST.
We found that both quadrupleWT GIST, in compari-
son with the other samples, strongly expressed several
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confirmed by quantitative PCR. ERG is a well-known
member of the erythroblast transformation-specific (ETS)
family of transcription factors, which function as tran-
scriptional regulators [37]. ETS proteins are regulated by
the mitogenic (RAS/MAPK) signalling transduction path-
way, and play an important role in cell differentiation, pro-
liferation, apoptosis and tissue remodelling [38]. There is
evidence for an oncogenic role of ERG and the other ETS
transcription factors in many human cancers, including
sarcomas, prostate cancer, and acute myeloid leukemia, in
most cases via chromosomal translocations [39-41]. More
recently, it has been shown that the IHC detection of ERG
may be a useful marker for vascular tumors, prostate car-
cinoma and ERG-rearranged Ewing sarcoma [42-44].
Over-expression of NTRK2 (TrkB) in quadrupleWT GIST
is also of interest, as NTRK2 helps regulated neuronal cell
function, including synaptic plasticity, differentiation,
growth, survival, and motility [45]. It has also been shown
that Trks regulate important processes in non-neuronal
cells, contributing to the pathogenesis of several kinds of
cancer, such as medullary thyroid carcinoma, prostate
cancer, non-small cell lung cancer, head and neck squa-
mous cell carcinoma and pancreatic cancer, in addition to
tumors of neural origin [46-51]. Given the relevant bio-
logical role played by Trks in cancer, different small mol-
ecule inhibitors have been developed and evaluated both
in mono-therapy and in combination with chemotherapy
in phase 1 and 2 clinical trials [52-58].
To our knowledge, the over-expression of ERG and
TrkB in GIST has not been previously reported. How-
ever, it is well known that ETV1, another member of
ETS family, is highly expressed in GIST and certain sub-
sets of ICC. ETV1 expression plays an important role in
regulating the growth of KIT mutant GIST cell lines
[59]. On the basis of our results, the overexpression of
ERG and TrkB seems to be a unique feature of the quad-
rupleWT GIST, suggesting that it could play a relevant
role in the pathogenesis of this subset of GIST. To trans-
late these observations into clinical practice, the over-
expression of both molecules could be investigated as
diagnostic markers of quadrupleWT GIST.
Conclusions
In conclusion, we report for the first time an integrated
genomic picture of the quadrupleWT GIST, using mas-
sively parallel sequencing and gene expression analyses,
and have identified a unique subset of GIST among the
family of the KIT/PDGFRA WT GIST [60]. The fre-
quency of this GIST subset amongst the family of GIST
will need to be defined in future studies as well as any
unique clinical-pathological features of this GIST subset,
including response to conventional GIST medical ther-
apy. In addition, ongoing studies of ICC developmentalbiology may help identify the “normal” precursor cells
that give rise to this unique GIST subgroup.
Methods
This study was approved by the institutional review
board of Azienda Ospedaliero-Universitaria Policlinico
S.Orsola-Malpighi, Bologna, Italy (approval number 113/
2008/U/Tess). All patients provided written informed
consent.
Patients and tumor samples
Fresh tissue specimens of GIST from 36 patients were
collected during the surgical operation, snap-frozen in li-
quid nitrogen and stored at −80°C until analysis. Pa-
tient’s characteristics are listed in Table 1.
Whole-Transcriptome Paired-End RNA Sequencing was
performed on 16 GIST, including 2 KITWT/PDGFRAWT
GIST patients without SDH-inactivating mutations (GIST_
133 and GIST_127), 2 KITWT/PDGFRAWT GIST patients
harbouring SDHA-mutations (GIST_7 and GIST_10), and
12 KIT or PDGFRA mutated GIST patients (7 harboured
exon 11 KIT mutations and 5 harboured exon 18 PDGFRA
mutations).
Whole-genome gene expression analysis was performed
on 9 of the above 16 GIST and extended to include an
additional 20 GIST: 1 KITWT/PDGFRAWT/SDHAmut GIST
and 19 KIT or PDGFRA mutated GIST, of which 13 har-
boured KIT mutations (12 in exon 11 and 2 in exon 9),
and 5 harboured PDGFRA mutations (2 in exon 12, 1 in
exon 14 and 2 in exon 18).
SDH status
SDH protein expression status was evaluated by both
immunohistochemistry (IHC) of SDHB and SDH sub-
units sequencing. IHC was performed on 4-μm sections
of FFPE GIST tumor samples. Rabbit polyclonal anti-
SDHB (HPA002868, Sigma-Aldrich, St Louis, MO, USA,
1:800) antibody was used. The sections were deparaffi-
nized, rehydrated, and subjected to the appropriate anti-
gen retrieval treatment (SDHB: microwave heating in
citrate buffer pH 6.0 at 100 1C for 40 min). After cooling
at room temperature, the activity of endogenous peroxi-
dises was inhibited using methanol/H2O2 (0.5% v/v) for
20 min. The sections were then washed in phosphate-
buffered saline (PBS, pH 7.2–7.4) and incubated with the
specific primary antibody overnight at room temperature.
After that, the sections were washed in PBS and treated
using the Novolink Polymer Detection System (Novocastra,
Newcastle upon Tyne, UK) according to the manufacturer’s
instructions. Liver tissues (for SDHB) were used as positive
controls. These tissues showed strong granular staining in
the cytoplasm and mitochondria with both of the
antibodies.
Table 1 Patient’s characteristic
ID Sex Array RNAseq Age Site Disease status at diagnosis KIT/PDGFRA/SDH mutational status
GIST_133 M X X 57 Duodenum Localized WT
GIST_127 F X X 63 Ileum Localized WT
GIST_07 F X X 27 Stomach Metastatic SDHA exon 9 p.S384X
GIST_10 M X X 29 Stomach Metastatic SDHA exon 2 p.R31X;
SDHA exon 13 p.R589W
GIST_188 F X 57 Duodenum Metastatic KIT exon 11 p.N564-L576 del + KIT exon 17 p.N822K
GIST_174 M X 59 Stomach Metastatic KIT exon 11 p.N564_L576 del + KIT exon 17 p.N822K
GIST_131 M X X 58 Ileum Localized KIT exon 11 p.V569_Y578 del
GIST_11 M X X 65 Stomach Localized KIT exon 11 p.557-558 del
GIST_134 F X X 65 Stomach Localized KIT exon p.V559D
GIST_124 M X X 70 Stomach Localized KIT exon 11 p.1765-1766 ins
GIST_150 F X 55 Stomach Localized KIT exon 11 p.P551_E554 del
GIST_165 M X 50 Stomach Localized PDGFRA exon 18 p.D842V
GIST_136 M X X 76 Stomach Localized PDGFRA exon 18 p.D842V
GIST_140 F X 45 Stomach Localized PDGFRA exon 18 p.D842V
GIST_141 M X 68 Stomach Localized PDGFRA exon 18 p.D842V
GIST_138 F X 75 Stomach Localized PDGFRA exon 18 p.D842V
GIST_02 F X 85 Stomach Localized KIT exon 11 p.V560D
GIST_04 M X 79 Stomach Localized KIT exon 9 p.AY502-503 ins
GIST_05 M X 68 Stomach Localized PDGFRA exon 12 p.SPDGHE566-571RIQ
GIST_08 M X 62 Stomach Localized KIT exon 11 p.V559D
GIST_09 M X 54 Stomach Localized KIT exon 11 TLQPYDHKWEEFP 574–585 ins at P585
GIST_12 F X 66 Stomach Localized PDGFRA exon 14 p.K646E
GIST_13 M X 46 Small intestine Localized KIT exon 11 p.V559D
GIST_14 M X 56 Stomach Localized KIT exon 11 p.WK557-558del
GIST_15 F X 64 Stomach Localized PDGFRA exon 18 DIMH p.842-845 DIMH del
GIST_16 F X 62 Stomach Localized KIT exon 11 p.L576P
GIST_20 M X 38 Small intestine Metastatic KIT exon 11 del MYEQW552-557 Z + KIT exon 18 A829P
GIST_22 F X 76 Stomach NA PDGFRA exon 18 p.D842V
GIST_23 F X 47 Stomach NA KIT exon 11 p.V559D
GIST_24 F X 18 Stomach Metastatic SDHA exon 8 p.L349R fs*11
GIST_26 M X 49 Stomach Localized PDGFRA exon 12 p.V561D
GIST_121 M X 71 Stomach Localized KIT exon 11 p.V559D
GIST_125 F X 48 Stomach Localized KIT exon 11 p.W557R
GIST_129 M X 59 Stomach Localized KIT exon11 p.Y553_V559 delins L
GIST_130 F X 79 Stomach Localized KIT exon 9 p.A502-Y503 ins
GIST_135 F X 61 Stomach Localized KIT exon 11 p.W557-E561 del
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(exon 1–6) and SDHD (exon 1–4) were sequenced on
fresh-frozen tumor specimens of KITWT/PDGFRAWT
GIST patients by Sanger Sequencing method. DNA was
extracted by the QIAmp DNA Mini kit (Qiagen, Milan,
Italy) in accordance with manufacturer’s directions. Each
exon was amplified with Polymerase Chain Reaction (PCR)amplification using specific primer pairs designed with Pri-
mer Express 3.0 Software (Applied Biosystem) to amplify
exons but not SDHA pseudo-genes located on chromo-
somes 3 and 5. Then, PCR products were purified with the
Qiaquick PCR purification kit (Qiagen, Milan, Italy) and
sequenced on both strands using the Big Dye Terminator
v1.1 Cycle Sequencing kit (Applied Biosystems). Sanger
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(Applied Biosystems).
Whole-transcriptome paired-end RNA sequencing
Total RNA was extracted from tumor specimens with
RNeasy Mini Kit (Qiagen, Milan, Italy), then cDNA li-
braries were synthesized from 250 ng total RNA with
TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego,
CA) according to the manufacturer’s recommendations.
Sequencing by synthesis was performed on HiScanSQ
sequencer (Illumina) at 75 bp in paired-end mode.
Whole-transcriptome sequencing yielded an average of
61 million mapped reads/patient, thus reaching an aver-
age coverage of 44X. Two SDHAmut tumor specimens
were previously analyzed by whole transcriptome se-
quencing at the Genome Sciences Centre (Vancouver,
Canada) [9].
Bioinformatic analysis
After demultiplexing and FASTQ generation (both steps
performed with Casava1.8, an application software spe-
cifically developed by Illumina), the paired-end reads
quality were analyzed with the function fastx_quality_-
stats (part of FASTX Toolkit available at http://hannon-
lab.cshl.edu/fastx_toolkit/index.html). Based on these
results we decided to trim each read of each sample at
74 bp in order to maximize sequence quality. The paired-
end reads were mapped with the pipeline TopHat/Bowtie
[61] on human reference genome HG19, collected from
UCSC Genome Browser (http://www.genome.ucsc.edu/).
After the alignment procedure the BAM file obtained was
manipulated with Samtools [62] in order to remove the
optical/PCR duplicate, to sort and to index it.
The analysis of gene expression was performed in two
steps: 1) the function htseq-count (Python package HTseq)
[63] was adopted to count the number of reads mapped on
known genes, included in the Ensembl release 72 annota-
tion features (http://www.ensembl.org); 2) the differential
expressed genes were evaluated using the R-Bioconductor
package edger [64]. DeFuse, ChimeraScan and FusionMap
packages were used to detect chimeric transcripts from
RNA-seq data.
Gene expression analysis
RNA was extracted using RNeasy Mini Kit (Qiagen),
quality-controlled and labeled as directed by the Affyme-
trix expression technical manual before hybridization to
U133Plus 2.0 arrays. Gene expression data were quantified
by the RMA algorithm, filtered and analyzed with super-
vised techniques by Limma modified t-test for the detec-
tion of differentially expressed genes. Differential expressed
genes hierarchical clustering and Principal Component
Analysis (PCA) were performed with Multiple Array
Viewer (MEV available at http://www.tm4.org/mev.html).The same software was used to represent the data in the
Figure 3 and Figure 4. Gene expression data of KIT/
PDGFRA-mutated and SDHA-mutated samples were pre-
viously reported [30].
Copy number analysis
Genomic DNA was labelled and hybridized to SNP array
Genome Wide SNP 6.0 (Affymetrix) following manufac-
turer’s instructions. Quality control was performed by
Contrast QC and MAPD calculation. Copy number ana-
lysis was performed by Genotyping Console and visual-
ized with Chromosome Analysis Suite (ChAS) Software
(Affymetrix). Hidden Markov Model algorithm was used
to detect amplified and deleted segments with stringent
parameters. To control for hyperfragmentation adjacent
segments separated by < 50 probes were combined into
one single segment, and only segments > 100 probes
were considered.
Quantitative PCR (qPCR)
Total RNA was reverse transcribed using Transcriptor
First Strand cDNA synthesis kit (Roche Applied Science,
Monza, Italy) with oligo-dT primers, according to the
manufacturer’s guidelines. Gene-specific primers were
designed with Primer Express 3.0 Software (Applied Bio-
systems) and qPCR was performed using FastStart Sybr
Green (Roche) on the LightCycler 480 apparatus
(Roche). DDCt method was used to quantify gene prod-
uct levels relative to the GAPDH and ATP5B house-
keeping genes. Significance was estimated by the Student’s
t test: * p-value < 0.05; ** p-value < 0.01, *** p-value < 0.01.
Western blot
Protein expression of NTRK2 was evaluated on 2
KITWT/PDGFRAWT/SDHWT/RAS-PWT GIST and 8 KIT
or PDGFRA or SDH mutant GISTs, of which fresh-
frozen tissues were available. Tissue were disrupted in
RIPA buffer (Sigma-Aldrich) supplemented with prote-
ases inhibitors and lysed for 1 h with gentle agitation at
4°C. Lysates were centrifuged at 13,000 × g for 15 min at
4°C and supernatants were stored at −80°C. Protein con-
centrations were determined with the BCA protein assay
(Pierce, Rockford, IL). Twenty micrograms of protein
were resolved on a 8% SDS-PAGE gel and transferred
onto polyvinylidene difluoride (PVDF) membranes. Non-
specific binding sites were blocked by incubation in
blocking buffer (PBS containing 0.1% Tween-20 with
5% w/v milk) for 1 h at room temperature. Membranes
were incubated overnight at 4°C, with the following pri-
mary antibodies: rabbit polyclonal TRKB antibody
(ab18987 Abcam 1:500), and rabbit polyclonal β-Tubulin
antibody (sc-9104 Santa Cruz Biotechnology, Santa Cruz,
CA, 1:500). Then, membranes were washed and incubated
with peroxidase conjugate secondary antibodies for 1 h at
Nannini et al. BMC Cancer 2014, 14:685 Page 10 of 12
http://www.biomedcentral.com/1471-2407/14/685room temperature. Antigens were revealed using Enhanced
Chemiluminescence Reaction (ECL Select, Amersham
Pharmacia Biotech, Les Ulis, France).
Nomenclature
KITWT No mutations of KIT
PDGFRAWT No mutations of PDGFRA
SDHWT No abnormalities of SDHA/B/C/D protein
expression and/or gene mutation
SDHAIHC – No expression of SDHA protein
SDHAIHC + Normal expression of SDHA protein
SDHBIHC – No expression of SDHB protein
SDHBIHC + Normal expression of SDHB protein
SDHAmut Mutation of SDHA protein (homozygous or
compound heterozygote)
SDHBmut Mutation of SDHB protein (homozygous or
compound heterozygote)
SDHCmut Mutation of SDHC protein (homozygous or
compound heterozygote)
SDHDmut – Mutation of SDHD protein (homozygous
or compound heterozygote)
Additional files
Additional file 1: Table S1. NTRK2 protein overexpression in KITWT/
PDGFRAWT/SDHWT/RAS-PWT GIST. Western blot immunostaining of NTRK2
was perfomed on proteins extracted from two quadrupleWT GIST and
from eight PDGFRA or KIT or SDH mutated GIST. HL-60 cell line protein
extract was used as positive control.
Additional file 2: Figure S1. NTRK2 protein overexpression in KITWT/
PDGFRAWT/SDHWT/RAS-PWT GIST. Western blot immunostaining of NTRK2
was perfomed on proteins extracted from two quadrupleWT GIST and
from eight PDGFRA or KIT or SDH mutated GIST. HL-60 cell line protein
extract was used as positive control.
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